{
    "info": {
        "nct_id": "NCT03366766",
        "official_title": "Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer",
        "inclusion_criteria": "* Pathologically confirmed non small cell lung cancer (NSCLC), not previously treated, with a plan to undergo surgery\n* Stage I-IIIA (stage I tumors must be >= 4 cm) per AJCC 8th edition\n* Tumor sample must be available for PD-L1 testing; archival tissue within 3 months of study enrollment will be used; if archival tissue is unavailable, a fresh biopsy will be taken\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* While blood cells 2000/ul or more\n* Absolute neutrophil count 1500/ul or more\n* Platelets 100,000/ul or more\n* Hemoglobin 9 g/dl or more; (transfusion permitted)\n* Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal\n* Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula or serum creatinine less than or equal to 1.5 x (ULN) upper limit of normal\n* Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 21 days of the study enrollment\n* Women of reproductive potential must use highly effective contraception methods to avoid pregnancy for 23 weeks after the last dose of study drugs; \"women of reproductive potential\" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level more than 40 mIU/mL\n* Men of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraception\n* All subjects must be able to comprehend and sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment\n* Any prior radiotherapy to the lung\n* Any prior treatment for NSCLC\n* Epidermal growth factor receptor (EGFR) or alkaline phosphatase (ALK) activating alteration\n* Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\n* Any history of a sever hypersensitivity reaction to any monoclonal antibody\n* Any history of allergy to the study drug components\n* Any concurrent malignancies- exceptions include- basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy; patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 3 years post-diagnosis\n* Participants with an active autoimmune disease or any other condition requiring systemic treatment with either corticosteroids within 14 days (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 30 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n* Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.â€¢ Patients with evidence of interstitial lung disease or active, non-infectious pneumonitis. Patients with a history of interstitial lung disease or non-infectious pneumonitis requiring treatment with steroids are also excluded.\n* Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS), active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)\n* Patients who have received a live vaccine within 30 days prior initiation of the systemic regimen\n* Patients must not be receiving any other investigational agents\n* Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial\n* Women must not be pregnant (as above) or breastfeeding",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 21 days of the study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Women of reproductive potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative serum or urine pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]",
                    "criterion": "pregnancy test sensitivity",
                    "requirements": [
                        {
                            "requirement_type": "minimum sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "IU/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 21 days of the study enrollment",
                    "criterion": "timing of pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "time before enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraception",
            "criterions": [
                {
                    "exact_snippets": "Men of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year",
                    "criterion": "contraceptive method use",
                    "requirements": [
                        {
                            "requirement_type": "failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs",
                    "criterion": "contraception duration after last dose",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 31,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "men who are azoospermic do not require contraception",
                    "criterion": "azoospermia",
                    "requirements": [
                        {
                            "requirement_type": "contraception requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count 1500/ul or more",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count 1500/ul or more",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed non small cell lung cancer (NSCLC), not previously treated, with a plan to undergo surgery",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed non small cell lung cancer (NSCLC)",
                    "criterion": "non small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously treated",
                    "criterion": "prior treatment for NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "plan to undergo surgery",
                    "criterion": "planned surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned intervention",
                            "expected_value": "surgery"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of reproductive potential must use highly effective contraception methods to avoid pregnancy for 23 weeks after the last dose of study drugs; \"women of reproductive potential\" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level more than 40 mIU/mL",
            "criterions": [
                {
                    "exact_snippets": "Women of reproductive potential must use highly effective contraception methods to avoid pregnancy for 23 weeks after the last dose of study drugs",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "\"women of reproductive potential\" is defined as any female who has experienced menarche",
                    "criterion": "menarche status",
                    "requirements": [
                        {
                            "requirement_type": "experienced menarche",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "undergone surgical sterilization",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "who is not postmenopausal",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "postmenopausal",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes",
                    "criterion": "menopause definition",
                    "requirements": [
                        {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "absence of other biological or physiological causes",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level more than 40 mIU/mL",
                    "criterion": "serum follicle stimulating hormone (FSH) level",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "FSH level",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All subjects must be able to comprehend and sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "must be able to comprehend ... informed consent document",
                    "criterion": "comprehension of informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be able to ... sign a written informed consent document",
                    "criterion": "ability to sign informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stage I-IIIA (stage I tumors must be >= 4 cm) per AJCC 8th edition",
            "criterions": [
                {
                    "exact_snippets": "Stage I-IIIA",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "I",
                                "II",
                                "IIIA"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "stage I tumors must be >= 4 cm",
                    "criterion": "stage I tumor size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "per AJCC 8th edition",
                    "criterion": "staging system",
                    "requirements": [
                        {
                            "requirement_type": "system",
                            "expected_value": "AJCC 8th edition"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor sample must be available for PD-L1 testing; archival tissue within 3 months of study enrollment will be used; if archival tissue is unavailable, a fresh biopsy will be taken",
            "criterions": [
                {
                    "exact_snippets": "Tumor sample must be available for PD-L1 testing",
                    "criterion": "tumor sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "archival tissue within 3 months of study enrollment will be used",
                    "criterion": "archival tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if archival tissue is unavailable, a fresh biopsy will be taken",
                    "criterion": "fresh tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "conditional",
                            "expected_value": "if archival tissue is unavailable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* While blood cells 2000/ul or more",
            "criterions": [
                {
                    "exact_snippets": "While blood cells 2000/ul or more",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2000,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin less than or equal to 1.5 x the upper limit of normal",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl",
                    "criterion": "total bilirubin in subjects with Gilbert syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula or serum creatinine less than or equal to 1.5 x (ULN) upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum creatinine less than or equal to 1.5 x (ULN) upper limit of normal",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin 9 g/dl or more; (transfusion permitted)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin 9 g/dl or more",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... less than or equal to 3 x the upper limit of normal",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets 100,000/ul or more",
            "criterions": [
                {
                    "exact_snippets": "Platelets 100,000/ul or more",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any prior radiotherapy to the lung",
            "criterions": [
                {
                    "exact_snippets": "Any prior radiotherapy to the lung",
                    "criterion": "prior radiotherapy to the lung",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any concurrent malignancies- exceptions include- basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy; patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 3 years post-diagnosis",
            "criterions": [
                {
                    "exact_snippets": "Any concurrent malignancies- exceptions include- basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy",
                    "criterion": "concurrent malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin",
                                "superficial bladder cancer",
                                "in situ cervical cancer that has undergone potentially curative therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 3 years post-diagnosis",
                    "criterion": "history of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "disease_free_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any history of a sever hypersensitivity reaction to any monoclonal antibody",
            "criterions": [
                {
                    "exact_snippets": "Any history of a sever hypersensitivity reaction to any monoclonal antibody",
                    "criterion": "hypersensitivity reaction to monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment",
            "criterions": [
                {
                    "exact_snippets": "participated in a study with an investigational agent or device within 2 weeks of enrollment",
                    "criterion": "prior participation in a study with an investigational agent or device",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received a live vaccine within 30 days prior initiation of the systemic regimen",
            "criterions": [
                {
                    "exact_snippets": "received a live vaccine within 30 days prior initiation of the systemic regimen",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Epidermal growth factor receptor (EGFR) or alkaline phosphatase (ALK) activating alteration",
            "criterions": [
                {
                    "exact_snippets": "Epidermal growth factor receptor (EGFR) ... activating alteration",
                    "criterion": "EGFR gene",
                    "requirements": [
                        {
                            "requirement_type": "activating alteration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alkaline phosphatase (ALK) activating alteration",
                    "criterion": "ALK gene",
                    "requirements": [
                        {
                            "requirement_type": "activating alteration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior treatment for NSCLC",
            "criterions": [
                {
                    "exact_snippets": "Any prior treatment for NSCLC",
                    "criterion": "prior treatment for NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women must not be pregnant (as above) or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Women must not be pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.â€¢ Patients with evidence of interstitial lung disease or active, non-infectious pneumonitis. Patients with a history of interstitial lung disease or non-infectious pneumonitis requiring treatment with steroids are also excluded.",
            "criterions": [
                {
                    "exact_snippets": "type I diabetes mellitus",
                    "criterion": "type I diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypothyroidism only requiring hormone replacement",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "only requiring hormone replacement"
                        }
                    ]
                },
                {
                    "exact_snippets": "skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment",
                    "criterion": "skin disorders (vitiligo, psoriasis, alopecia)",
                    "requirements": [
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "not requiring systemic treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "conditions not expected to recur in the absence of an external trigger",
                    "criterion": "conditions not expected to recur without external trigger",
                    "requirements": [
                        {
                            "requirement_type": "recurrence_expectation",
                            "expected_value": "not expected to recur in the absence of an external trigger"
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of interstitial lung disease or active, non-infectious pneumonitis",
                    "criterion": "interstitial lung disease or active, non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "evidence_of_disease",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of interstitial lung disease or non-infectious pneumonitis requiring treatment with steroids",
                    "criterion": "history of interstitial lung disease or non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring treatment with steroids"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways",
            "criterions": [
                {
                    "exact_snippets": "Any prior therapy with anti-PD-1",
                    "criterion": "prior therapy with anti-PD-1 antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior therapy with ... anti-PD-L2",
                    "criterion": "prior therapy with anti-PD-L2 antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior therapy with ... anti-CTLA-4 antibody",
                    "criterion": "prior therapy with anti-CTLA-4 antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior therapy with ... any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways",
                    "criterion": "prior therapy with antibody or drug targeting T-cell co-stimulation or immune checkpoint pathways",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS), active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)",
            "criterions": [
                {
                    "exact_snippets": "known human immunodeficiency virus infection (HIV 1/2 antibodies)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acquired immunodeficiency syndrome (HIV/AIDS)",
                    "criterion": "AIDS",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any history of allergy to the study drug components",
            "criterions": [
                {
                    "exact_snippets": "Any history of allergy to the study drug components",
                    "criterion": "allergy to study drug components",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with an active autoimmune disease or any other condition requiring systemic treatment with either corticosteroids within 14 days (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 30 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.",
            "criterions": [
                {
                    "exact_snippets": "active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other condition requiring systemic treatment with either corticosteroids within 14 days (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 30 days of randomization",
                    "criterion": "systemic treatment with corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other condition requiring systemic treatment with either corticosteroids within 14 days (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 30 days of randomization",
                    "criterion": "systemic treatment with immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled intercurrent illnesses",
                    "criterion": "intercurrent illnesses",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection requiring systemic therapy",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial",
                    "criterion": "psychiatric or substance abuse disorder(s)",
                    "requirements": [
                        {
                            "requirement_type": "known diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interferes with cooperation with trial requirements",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not be receiving any other investigational agents",
            "criterions": [
                {
                    "exact_snippets": "Patients must not be receiving any other investigational agents",
                    "criterion": "receipt of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}